Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP.AVXL · Entity 6086 | Director · President and CEO | January 06, 2026 | January 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAVEX LIFE SCIENCES CORP.
Report date January 06, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.58 · Expires 2035-03-31 | Direct | 125,000 |
Reported balance
After 2026-01-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-06 · Grant · Acquired 125,000 · Balance 125,000 F1: On March 31, 2025, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was a Second Regulatory dialogue for blarcamesine. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 31, 2025, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was a Second Regulatory dialogue for blarcamesine. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 07, 2017 Filed Sep 8, 2017 19:20 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $4.76 | $1,785.00 |
DisclosureSEC source: 0001615774-17-004994 · s107446_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,007,000 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| September 05, 2017 Filed Sep 5, 2017 14:20 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $4.90 | $1,837.50 |
DisclosureSEC source: 0001615774-17-004918 · s107406_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,006,625 F1 · kind: The purchase reported in this form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| August 31, 2017 Filed Aug 31, 2017 14:45 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $4.48 | $1,680.00 |
DisclosureSEC source: 0001615774-17-004886 · s107395_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,006,250 F1 · kind: The purchase reported in this form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| August 28, 2017 Filed Aug 29, 2017 11:12 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $4.44 | $1,665.00 |
DisclosureSEC source: 0001615774-17-004809 · s107368_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,005,875 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| August 24, 2017 Filed Aug 25, 2017 14:18 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $4.54 | $1,702.50 |
DisclosureSEC source: 0001615774-17-004745 · s107350_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,005,500 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| August 21, 2017 Filed Aug 21, 2017 11:42 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $4.07 | $1,526.25 |
DisclosureSEC source: 0001615774-17-004587 · s107276_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,005,125 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| August 18, 2017 Filed Aug 18, 2017 16:54 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $3.81 | $1,428.75 |
DisclosureSEC source: 0001615774-17-004574 · s107265_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,004,750 F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| August 14, 2017 Filed Aug 14, 2017 17:12 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 375 | $3.70 | $1,387.50 |
DisclosureSEC source: 0001615774-17-004399 · s107188_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,004,375 F1 · kind: The purchase reported in this form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| August 11, 2017 Filed Aug 11, 2017 16:35 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | PurchaseCommon Stock | 750 | $3.55 | $2,662.50 |
DisclosureSEC source: 0001615774-17-004281 · s107162_form4.xml · nonDerivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,004,000 F1 · kind: The purchase reported in this form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document |
| May 12, 2017 Filed May 15, 2017 17:15 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $5.92 | $0.00 |
DisclosureSEC source: 0001615774-17-002453 · s106224_form4.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2027-05-12 F1 · derivative.exercise_date: The options shall vest quarterly over a three-year period commencing on June 30, 2017. Read SEC document |
| September 22, 2016 Filed Sep 26, 2016 17:12 UTC | ANAVEX LIFE SCIENCES CORP. AVXL · Entity 6086 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001615774-16-007378 · s104214_form4.xml · derivative · entry 1 MISSLING CHRISTOPHER U · CIK 0001196573 · Director · President, CEO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2026-09-22 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.